Sign In
Buy HBP
$10.70
+0 (+0%)
At Close: Aug 17, 2022
Vancouver, British Columbia – TheNewswire - June 12, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
05:15pm, Wednesday, 03'rd Jun 2026
Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “ HBP ”, OTC PINK: “ HBPCF ”, FRANKFURT: “ HBP0 ”) (“ Helix ” or the “ Company ”), a clin
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
04:15pm, Friday, 22'nd May 2026
Toronto, Ontario – TheNewswire - May 22, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncol
Helix BioPharma (TSE:HBP) Stock Passes Above Fifty Day Moving Average – Should You Sell?
04:09am, Saturday, 18'th Apr 2026
Helix BioPharma Corp. (TSE: HBP - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of C$1.88 and traded as high as
Toronto, Ontario – TheNewswire - 16 March, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage onc
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
04:30pm, Thursday, 05'th Feb 2026
(Toronto, Ontario; February 5, 2026) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage on
Helix BioPharma (TSE:HBP) Stock Passes Below Fifty Day Moving Average – Time to Sell?
04:12am, Saturday, 10'th Jan 2026
Helix BioPharma Corp. (TSE: HBP - Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$2.27 and traded as low as C$2.15. Helix
Toronto, Ontario – TheNewswire - 15 December, 2025 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
12:45pm, Wednesday, 29'th Oct 2025
Toronto, Ontario – TheNewswire - 29 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology c
Helix BioPharma Responds to Market Activity
11:35am, Monday, 06'th Oct 2025
Toronto, Ontario – TheNewswire - 6 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology co
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
04:15pm, Tuesday, 09'th Sep 2025
Toronto, Ontario – TheNewswire - 9 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
12:00pm, Tuesday, 09'th Sep 2025
TORONTO, ON / ACCESS Newswire / September 9, 2025 / Helix BioPharma Corp. (TSX:HBP)(OTC:HBPCF)(FRANKFURT:HBP0) ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
06:00pm, Friday, 22'nd Aug 2025
Toronto, Ontario (22 August 2025) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncology comp
Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC
11:10am, Wednesday, 13'th Aug 2025
Toronto, Ontario – TheNewswire - 13 August 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), a clinical-stage oncolo
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
07:00pm, Monday, 16'th Jun 2025
(Toronto, Ontario) – Helix BioPharma Corp. - TheNewswire - (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company s
